Controversial AI-based STI screening app faces regulatory scrutiny
HeHealth’s AI-powered Calmara app, which claimed to offer rapid and confidential sexual health screening through genital images, has been shut down following an inquiry by the Federal Trade Commission (FTC). The app’s bold claims and unconventional approach to STI detection raised concerns about its scientific validity and privacy implications.
Key details of the FTC investigation:
- The FTC questioned the scientific basis of HeHealth’s claims, including its assertion of detecting over 10 STIs with up to 94% accuracy
- Concerns were raised about potential conflicts of interest, as HeHealth paid some study authors
- The main study cited by the company only assessed four types of STIs, not the claimed 10
- Training data for the AI model included images from users without confirmed diagnostic tests
Implications for AI in healthcare and consumer protection
This case highlights the challenges of regulating AI-powered health technologies and the importance of consumer protection in the digital age. It underscores the need for rigorous scientific validation and transparency in health-related AI applications. The FTC’s actions demonstrate a growing focus on protecting consumers from potentially misleading or harmful AI-driven products, especially in sensitive areas like sexual health.
